Abstract 14770: Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From the FOURIER Trial

医学 传统PCI Evolocumab公司 血运重建 心脏病学 内科学 经皮冠状动脉介入治疗 支架 心肌梗塞 外科 载脂蛋白B 胆固醇 载脂蛋白A1
作者
Kazuma Oyama,Remo H M Furtado,Antônio Fagundes,Thomas A. Zelniker,Minao Tang,Julia Kuder,Sabina A. Murphy,Andrew Hamer,Huei Wang,Anthony Keech,Terje R. Pedersen,Robert P. Giugliano,Marc S. Sabatine,Brian Bergmark
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:142 (Suppl_3) 被引量:3
标识
DOI:10.1161/circ.142.suppl_3.14770
摘要

Introduction: Although PCSK9 inhibitors induce plaque regression and reduce the risk of coronary revascularization overall, their ability to specifically reduce the risk of complex coronary atherosclerosis requiring revascularization has not been explored. Methods: FOURIER was a randomized trial of the PCSK9 inhibitor evolocumab vs. placebo in 27,564 patients with ASCVD on statin therapy (median achieved LDL-C 32 mg/dL vs. 89 mg/dL) followed for a median of 2.2 years. The study database was blindly reviewed to assess characteristics of coronary revascularization procedures. Complex revascularization was the composite of complex PCI (per GLOBAL LEADERS criteria, at least one of: multivessel PCI, 3 or more stents implanted, 3 or more lesions treated, bifurcation PCI with 2 or more stents, or total stent length >60 mm) or CABG. PCI complications included no-reflow, side branch loss, thrombus formation, major dissection, or perforation. The effects of evolocumab on types of revascularization and PCI complications were evaluated using Cox proportional hazards models. Results: 1724 patients underwent revascularization procedures during follow-up. Evolocumab reduced the risk of non-complex PCI by 22% (HR 0.78; 95%CI 0.70-0.88; P<0.001) and the risk of complex revascularization by 29% (HR 0.71; 95%CI 0.61-0.84; P<0.001), including complex PCI by 33% (HR 0.67; 95%CI 0.54-0.84; P<0.001) and CABG by 24% (HR 0.76; 95%CI 0.60-0.96; P=0.019; Figure). The incidence of reported PCI complications tended to be lower with evolocumab (HR 0.74; 95% CI 0.49-1.11). Conclusions: Adding evolocumab to statin therapy reduced the risk of developing complex coronary disease requiring revascularization, including complex PCI and CABG individually. Together with prior coronary imaging findings, these data suggest very aggressive LDL-C lowering to <1 mmol/L has beneficial effects on coronary atherosclerosis burden, anatomical complexity, and the need for intervention.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
贤惠的平松完成签到,获得积分10
刚刚
sssssss发布了新的文献求助10
1秒前
沐沐发布了新的文献求助10
1秒前
Ssyong发布了新的文献求助10
1秒前
1秒前
现安完成签到 ,获得积分10
1秒前
虚心蜻蜓完成签到,获得积分10
1秒前
科研通AI6.4应助七听采纳,获得30
1秒前
2秒前
慕青应助vcccc采纳,获得10
2秒前
3秒前
3秒前
3秒前
3秒前
4秒前
卡乐瑞咩吹可完成签到,获得积分0
4秒前
4秒前
5秒前
lili完成签到,获得积分10
5秒前
ZX_Young应助大胆的乐荷采纳,获得10
5秒前
Aprilapple发布了新的文献求助10
5秒前
星辰大海应助rick3455采纳,获得10
5秒前
5秒前
DrLinh完成签到,获得积分10
6秒前
NexusExplorer应助古月博士采纳,获得10
6秒前
6秒前
物理丫丫完成签到,获得积分20
6秒前
zhangzhang发布了新的文献求助30
6秒前
7秒前
一只否酱完成签到,获得积分10
8秒前
小唐发布了新的文献求助10
8秒前
bear发布了新的文献求助10
8秒前
嘉嘉完成签到,获得积分10
8秒前
8秒前
8秒前
8秒前
9秒前
bkagyin应助米米采纳,获得10
9秒前
英俊的铭应助zzz采纳,获得10
9秒前
天天快乐应助2522121033采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
HYDROLYSE ACIDE DE QUELQUES DIOXASPIROCYCLANES 1000
Navigating Normative Orders. Interdisciplinary Perspectives 800
1 Peter and Christ's Descent to the Dead in Its Early Christian Reception 700
Essentials of Carbohydrate Chemistry and Biochemistry, 4th Edition 600
Organizational Behavior 510
Management and the Arts 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7741762
求助须知:如何正确求助?哪些是违规求助? 9290307
关于积分的说明 20200680
捐赠科研通 7320230
什么是DOI,文献DOI怎么找? 3306862
关于科研通互助平台的介绍 2458977
邀请新用户注册赠送积分活动 2317319